PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10820139-8 2000 The mean activities of microsomal CYP1A2, CYP2B6, and CYP3A4/5 from modafinil-treated hepatocytes were higher (up to 2-fold) than those in the solvent-treated controls but were less than those produced by reference inducers of these enzymes. Modafinil 68-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 54-60 18076219-4 2008 Study 2 evaluated the potential for armodafinil to induce gastrointestinal and hepatic CYP3A4 activity using intravenous and oral midazolam as the probe substrate. Modafinil 36-47 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 87-93 18076219-17 2008 CONCLUSIONS: Armodafinil did not induce CYP1A2 but was a moderate inducer of CYP3A4 and a moderate inhibitor of CYP2C19 in healthy subjects. Modafinil 13-24 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 77-83 18076219-19 2008 Dosage adjustments may be required for drugs that are substrates of CYP3A4 (e.g. ciclosporin, triazolam) and CYP2C19 enzymes (e.g. diazepam, phenytoin) when administered with armodafinil. Modafinil 175-186 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 68-74 11823757-1 2002 BACKGROUND: Modafinil has been reported to produce a concentration-related induction of CYP3A4/5 activity in vitro in primary cultures of human hepatocytes. Modafinil 12-21 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-94 11823757-8 2002 CONCLUSION: Modafinil induced CYP3A4/5 activity in humans in vivo, suggesting that there is potential for metabolic drug-drug interactions between modafinil and substrates of CYP3A4/5. Modafinil 12-21 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-36 11823757-8 2002 CONCLUSION: Modafinil induced CYP3A4/5 activity in humans in vivo, suggesting that there is potential for metabolic drug-drug interactions between modafinil and substrates of CYP3A4/5. Modafinil 12-21 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 175-181 10820139-10 2000 Overall, modafinil was shown to have effects on human hepatic CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 activities in vitro. Modafinil 9-18 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-105 34633961-6 2021 Modafinil has the ability to induce the activity of CYP3A4 and consequently decrease the bioavailability of hydrocortisone. Modafinil 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 52-58 34623637-0 2022 Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil. Modafinil 127-136 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 104-123 29178272-8 2018 CONCLUSIONS: These data support consideration of the risk of clinically relevant metabolic drug-drug interactions perpetrated by modafinil when this drug is co-administered with drugs that are primarily cleared by CYP2C19 (single modafinil dose or steady state modafinil dosing) or CYP3A4 (steady state modafinil dosing only) catalysed metabolic pathways. Modafinil 129-138 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 282-288 33937953-3 2021 This phase I, open-label, two-period study evaluated the impact of a moderate CYP3A inducer, modafinil, on the safety and pharmacokinetics of lorlatinib. Modafinil 93-102 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 78-83 26181194-1 2015 INTRODUCTION: Armodafinil, a moderate inducer of cytochrome P450 (CYP) 3A4, has been studied as adjunctive therapy to maintenance medications for major depressive episodes associated with bipolar I disorder. Modafinil 14-25 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-74 26717524-3 2015 A recent pharmacokinetic (PK) study suggested that armodafinil (250 mg/d) reduces key PK parameters of risperidone by about 50%, and key PK parameters of 9-hydroxyrisperidone (paliperidone) by about 20%-30%, probably through induction of CYP3A4. Modafinil 51-62 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 238-244 26387027-10 2015 CONCLUSION: Consistent with CYP3A4 induction, risperidone and 9-hydroxyrisperidone systemic exposure was reduced in the presence of armodafinil. Modafinil 132-143 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 28-34 26181194-2 2015 We evaluated the effect of daily dosing with armodafinil on the pharmacokinetics and safety of the CYP3A4 substrate aripiprazole, an atypical antipsychotic used to treat bipolar I disorder. Modafinil 45-56 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-105 26181194-7 2015 Armodafinil reduced systemic exposure to aripiprazole (Cmax, - 8%; AUC0- , -34%) and dehydro-aripiprazole, which is both formed and eliminated in part via CYP3A4 (Cmax, - 10%; AUC0- , - 32%). Modafinil 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 155-161 25438721-3 2015 Armodafinil and the mood stabilizer carbamazepine are both inducers of and substrates for cytochrome P450 (CYP3A4). Modafinil 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 107-113 25438721-15 2015 IMPLICATIONS: Systemic exposure to both carbamazepine and armodafinil was reduced after pretreatment with the other drug; systemic exposure to the metabolites of each drug, which are formed via CYP3A4, was increased. Modafinil 58-69 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 194-200 22434147-2 2012 Here, we show that modafinil, a well-known inducer of hepatic CYP enzymes, also increases CYP3A4 expression in human-derived neuron-like SH-SY5Y cells. Modafinil 19-28 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 90-96 25047407-2 2014 This open-label, single-centre, 2-period study evaluated the effect of armodafinil, a moderate inducer of cytochrome-P450 (CYP) isoenzyme CYP3A4, on the pharmacokinetics and safety of ziprasidone, an atypical antipsychotic used to treat bipolar I disorder and metabolized in part by CYP3A4. Modafinil 71-82 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 138-144 25047407-2 2014 This open-label, single-centre, 2-period study evaluated the effect of armodafinil, a moderate inducer of cytochrome-P450 (CYP) isoenzyme CYP3A4, on the pharmacokinetics and safety of ziprasidone, an atypical antipsychotic used to treat bipolar I disorder and metabolized in part by CYP3A4. Modafinil 71-82 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 283-289 22434147-3 2012 Upregulation of CYP3A4 by modafinil was associated with increased retinoic acid (RA) degradation, which could be blocked by specific CYP3A4 inhibitor erythromycin. Modafinil 26-35 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 16-22 22434147-3 2012 Upregulation of CYP3A4 by modafinil was associated with increased retinoic acid (RA) degradation, which could be blocked by specific CYP3A4 inhibitor erythromycin. Modafinil 26-35 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 133-139 21903893-2 2012 This open-label study in 37 adults with schizophrenia evaluated whether a drug-drug interaction occurs between armodafinil (a moderate CYP3A4 inducer) and the atypical antipsychotic quetiapine (primarily metabolized by CYP3A4). Modafinil 111-122 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 135-141